Background

Katie is a Research Officer under the Viral Hepatitis Elimination Program, working on improving treatment access for hepatitis C. Her interests are health equity & economics, infectious disease epidemiology and health policy. Her research approach is interdisciplinary, using a combination of mathematical modelling and empirical work.

Katie is a consultant for the World Health Organization, developing tools and policy for national strategic planning in maternal and child health. Katie also works on health economics in relation to HIV, hepatitis C and tuberculosis treatment, and on vector-borne disease control.

Positions

• 2020 - ongoing - Research Officer, Burnet Institute, Melbourne, Australia
• 2018 - ongoing - Consultant, World Health Organization, Department of Reproductive Health & Research, Geneva, Switzerland
• 2018 - 2018 - Environmental Scientist, Instituto Nacional de Pesquisas Espaciais (INPE), São José dos Campos, Brazil
• 2016 - Scientific Enterprise Consultant, The Nasio Trust, Musanda, Western, Kenya
• 2014 - 2015 - Research Officer, International Prevention Research Institute (IPRI), Lyon, France
• 2012 - Research Assistant, University of Strathclyde, Department of Mathematics and Statistics, Glasgow, UK

Qualifications

• 2019 - PhD Zoology, University of Oxford
• 2014 - MSc Epidemiology, Imperial College London
• 2013 - BA Philosophy, University of Cambridge

Projects (3)

Current (3)

• 

  The elimination of hepatitis C as a global public health threat

• 

  The Optimise Study: Optimising Isolation, Quarantine and Distancing for COVID-19

• 

  The QuickStart Study

Publications (10)

2021 (3)

• Estimation of benzathine penicillin G demand for congenital syphilis elimination with adoption of dual HIV/syphilis rapid diagnostic tests in eleven high burden countries.
  Shah S, Garg S, Heath K, Ofili O, Bansal Y, Seghers F, Storey A, Taylor M
  PLoS One. 2021 Aug; 16(8):e0256400
• Reaching UNAIDS 95-95-95 targets worldwide: predicted benefits and treatment costs with generic manufacture.
  Heath K, Levi J, Hill A
  AIDS. 2021 Jun; Epub ahead of print
• The Optimise Study: Social networks and mixing patterns. (PUBLIC HEALTH REPORT)
  Saich F, Heath K, Altermatt A, Munari S, Merner B, Hill S, Lusher D, Radhitio Sadewo G, Wang P, Pedrana A, Gibney K, Hellard M
  The Optimise Study. 2021 Apr; Report 5:1-12

2020 (2)

• Nutritional availability and larval density dependence in Aedes aegypti
  Katherine Heath, Robert S. Paton, Anthony J. Wilson, Michael B. Bonsall
  Ecol Entomol. 2020 Oct; 45(5):929-944
• Minimum costs to manufacture new treatments for COVID-19.
  Hill A, Wang J, Levi J, Heath K, Fortunak J
  J Virus Erad. 2020 Apr; 6(2):61-69

2019 (1)

• Most new HIV infections, vertical transmissions and AIDS-related deaths occur in lower-prevalence countries.
  Joe Kempton, Andrew Hill, Jacob A Levi, Katherine Heath, Anton Pozniak
  J Virus Erad. 2019 Apr; 5(2):92-101

2018 (2)

• Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C.
  Katherine Heath
  Clinicoecon Outcomes Res. 2018 Sep; 10:539-550
• The impact of HIV prevalence, conflict, corruption, and GDP/capita on treatment cascades: data from 137 countries.
  Jacob Levi, Anton Pozniak, Katherine Heath, Andrew Hill
  J Virus Erad. 2018 Apr; 4(2):80-90

2015 (2)

• Higher risks of mother-to-child HIV transmission in countries with lower HIV prevalence: UNAIDS 2013 results for 32 countries with generalised epidemics.
  Andrew Hill, Thomas Dauncey, Jake Levi, Katherine Heath, Carmen Perez Casas
  J Virus Erad. 2015 Oct; 1(4):257-263
• Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response.
  Bryony Simmons, Jawaad Saleem, Katherine Heath, Graham S Cooke, Andrew Hill
  Clin Infect Dis. 2015 Sep; 61(5):730-740

News Articles (1)

2020 (1)

• Drug pricing a barrier to HIV elimination